



2019 UN Global Compact Communication on Progress

AMGEN[®]

Our Ongoing Commitment to the United Nations Global Compact

We are pleased to present Amgen's Communication on Progress relating to the United Nations Global Compact. Although this update focuses on our activities during 2019, I thought it important to take a moment to discuss the many ways Amgen is responding to the current COVID-19 pandemic.¹

- **Our employees** – We are providing our employees around the world with a wealth of resources to stay physically and mentally healthy and productive, whether they are working at home or continuing to come to an Amgen facility to perform mission-critical work. Additionally, we have expanded our staff volunteer program to support our employees who have medical training and wish to volunteer on the front lines of the COVID-19 pandemic.
- **Our patients** – Amgen produces medicines that treat some of the world's most serious illnesses, including cancer and heart disease. At a time when healthcare systems around the world are being stretched to their limit, we have continued to provide an uninterrupted clinical and commercial supply of medicines for patients around the world and do not currently anticipate a shortage of our medicines due to COVID-19. With respect to our clinical trials, study start-up activities are continuing where possible to allow rapid site activation and enrollment when that becomes feasible, and study procedures are being implemented consistent with recent guidance from regulators to maintain patient safety and study data integrity.
- **Our science** – While infectious disease has not been an area of focus for Amgen historically, we are leveraging our strengths in antibody engineering with our partner Adaptive Biotechnologies

to develop an antibody to potentially prevent or treat COVID-19, and we are also part of a broad coalition of companies and government agencies, led by the National Institutes of Health, working to accelerate COVID-19 treatments and vaccines. Otezla® (apremilast), an oral treatment approved in more than 50 countries for inflammatory diseases such as psoriasis and psoriatic arthritis, is expected to be investigated as a potential immunomodulatory treatment in adult patients with COVID-19 in upcoming platform trials. Additionally, our deCODE Genetics subsidiary has completed significant molecular epidemiology work on SARS-CoV-2 in Iceland.

- **Our communities** – Amgen and the Amgen Foundation have made an initial commitment of up to \$12.5 million to support COVID-19 emergency response efforts and is directing these funds toward communities globally where Amgen has a significant presence, patient-focused organizations that are mounting their own response efforts and international relief efforts by Direct Relief and International Medical Corps. Additionally, the Amgen Foundation is a proud sponsor of two online learning platforms—Khan Academy and LabXchange—that are providing free, world-class educational content to millions of students around the world at a time when many are no longer able to go to school.

In 2020, Amgen celebrates the fortieth anniversary of our founding. Over the years, our most important contributions to society have come through the development of innovative medicines to treat seriously ill patients. Our ongoing commitment to advance the principles of the UN Global Compact reflects our dedication to contributing to the greater global good in many other ways—



operating ethically, promoting diversity in the workplace and reducing our environmental footprint, to name just a few. We are delighted to share in this Communication on Progress our recent work in these areas and many others.

Robert A. Bradway

Robert A. Bradway
Chairman and Chief Executive Officer

¹As of April 30, 2020.

Highlights of Progress

This Communication on Progress (COP) summarizes our progress in the four key areas of the Global Compact principles: Environment, Labor, Human Rights and Anti-Corruption. Our commitment to serve patients drives the many Amgen programs, procedures, policies and reporting aligned with the UNGC principles, and we continue to work to enhance our approaches and performance in alignment with those principles. This section of the COP provides highlights of our 2019 progress and is followed by a table that indicates where to find additional information about Amgen's programs and progress that align with the Global Compact.

Some of our key areas of progress in 2019 include the following:

Amgen sets official Guinness World Record™ for most osteoporosis screenings for an osteoporosis campaign in 24 hours. The campaign took place in Brazil, Canada, Colombia, Egypt, Kuwait, Lebanon, Mexico, Saudi Arabia, South Africa and Turkey with 6,056 tracked screenings on May 5, 2019.

Amgen met and exceeded its 2020 targets for reducing carbon emissions and water use ahead of schedule. Our innovative use of next-generation biomanufacturing is providing significant environmental benefits. Compared with a traditional plant, our next-generation facility in Singapore each year uses approximately 268,000 less gigajoules of energy and 82,000 fewer cubic meters of water, while also reducing carbon emissions by 8,800 metric tons. We are applying the same approach to the new manufacturing facility currently under construction in Rhode Island.

The Amgen Foundation committed \$11.5M to a collaboration with Harvard University to create LabXchange, a new online community for learning, sharing and collaboration. The LabXchange platform, which launched with a focus in biology,

offers digital instruction and virtual lab experiences to high school and college students, enabling them to gain meaningful exposure to the scientific process. It will also include online networking focused on collaboration and mentoring.

Amgen entered into a strategic collaboration with BeiGene to expand access to Amgen oncology products in China. Cancer is a leading cause of death in China, positioned to become an even greater public health issue as the Chinese population ages. BeiGene will commercialize three of our products in China, and we will collaborate with BeiGene to jointly develop a portion of our oncology portfolio in China and globally.

Amgen increased the number of our suppliers that we assess for sustainability performance by 43 percent. We assess our suppliers on their sustainability performance in compliance with the Amgen Supplier Code of Conduct. Increasing the number of suppliers assessed improves our ability to work with our supply chain to improve their sustainability performance.

Amgen and the CDC Foundation entered into a global partnership to increase awareness and knowledge of cardiovascular disease (CVD) globally. With CVD recognized as the number one cause of death worldwide, this five-year effort aims to expand the evidence base for CVD risk factors, with a focus on low- and middle-income countries, by supporting the collection and analysis of data to improve understanding of the causes of CVD and interventions that may improve patient outcomes.

We evolved and enhanced our strategy for Diversity, Inclusion and Belonging. At Amgen, we believe that a diverse and inclusive workforce empowers us to innovate and better represent patients and are committed to an inclusive, diverse and safe workplace for our employees. Priorities have been established to increase the



“The LabXchange platform has helped me support students with diverse backgrounds, so they can feel confident and prepared for understanding lab experiences.”
— Mary L., a biology teacher at Weston High School in Massachusetts

percentage of women in management on a global basis and, in the U.S., to increase the percentage of African Americans and Hispanics in senior management positions.

We continued our commitment to business ethics as one of our core values. In 2019, 100 percent of our staff trained on our Code of Conduct, and 200+ leaders completed their Global Ethics & Compliance Declaration Program, which calls for leaders in selected leadership roles to execute an ethics and compliance engagement plan and sign an annual declaration.

Amgen continued the implementation of our collaboration with the Lazarex Cancer Foundation on their IMPACT (IMproving Patient Access to Cancer Clinical Trials) program. This program focuses on improving clinical trial diversity for trials of medicines to address cancer.

Summary of Relevant Reporting

Amgen provides extensive reporting on policies and progress aligned with the UNGC on our website. Below is a summary table providing links to existing reporting aligned with the major categories of UNGC principles.

Amgen Policies, Programs and Reporting	UNGC Principles Categories			
	Human Rights	Labor	Environment	Anti-Corruption
Responsibility Highlights Report	•	•	•	•
Commitment to Corporate Social Responsibility	•	•	•	
Staff Code of Conduct	•	•	•	•
Diversity and Inclusion	•	•		
Access to Medicine	•			
Staff Health and Safety	•	•		
Staff Wellness	•	•		
Environment, Health and Safety Policy		•	•	
Non-Discrimination	•	•		
Environmental Sustainability Commitment			•	
Environmental Sustainability Performance			•	
Amgen Foundation	•			
Amgen Safety Net Foundation	•			
Supplier Sustainability	•	•	•	•
California Supply Chain Transparency Act	•	•		
Conflict Minerals Policy	•	•		
Conflict Minerals Report	•	•		
Supplier Diversity	•	•		
Anti-Corruption and U.S. Foreign Corrupt Practices				•
Interactions with Healthcare Providers				•

Forward-Looking Statements

This communication contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company, including Adaptive Biotechnologies (including statements regarding such collaboration's ability to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19), BeiGene, Ltd., or the Otezla acquisition, including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, outcomes, progress, or effects relating to studies of Otezla as a potential treatment for COVID-19, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory

developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution

of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

©Amgen May 2020. All Rights Reserved.